Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Repligen Corporation (NASDAQ:RGEN) have earned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $174.5833.

RGEN has been the subject of several recent analyst reports. UBS Group dropped their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Weiss Ratings lowered shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Barclays cut their price target on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th.

Repligen Price Performance

NASDAQ:RGEN opened at $113.76 on Friday. The firm has a market capitalization of $6.41 billion, a price-to-earnings ratio of 133.84, a PEG ratio of 2.32 and a beta of 1.14. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. The business has a 50 day simple moving average of $146.43 and a 200-day simple moving average of $146.72. Repligen has a 1 year low of $102.96 and a 1 year high of $175.77.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. During the same quarter in the previous year, the company posted $0.44 EPS. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts forecast that Repligen will post 1.72 EPS for the current year.

Insider Activity at Repligen

In other news, Director Karen A. Dawes sold 275 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the sale, the director directly owned 91,821 shares in the company, valued at approximately $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of large investors have recently bought and sold shares of RGEN. Rhenman & Partners Asset Management AB lifted its position in shares of Repligen by 333.3% during the second quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock worth $2,425,000 after purchasing an additional 15,000 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Repligen by 34.1% in the second quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock worth $2,158,000 after purchasing an additional 4,417 shares during the last quarter. Delta Investment Management LLC bought a new position in shares of Repligen in the third quarter worth about $6,779,000. Congress Asset Management Co. increased its stake in Repligen by 43.4% in the 3rd quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock worth $29,219,000 after buying an additional 66,142 shares during the period. Finally, Schroder Investment Management Group lifted its holdings in Repligen by 123.2% during the 3rd quarter. Schroder Investment Management Group now owns 460,609 shares of the biotechnology company’s stock valued at $61,570,000 after buying an additional 254,212 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.